List view / Grid view
Discover how Domain Therapeutics is using its deep knowledge of GPCR biology to create novel therapeutics with the potential to combat inflammatory diseases such as atopic dermatitis, IBD and arthritis.
GPCRs are crucial drug targets, but their complex structures present significant challenges in drug discovery. In this article, Domainex’s Philip Rawlins explores how fragment-based screening and innovative technologies like PoLiPa are helping to overcome these hurdles, with a focus on the Adenosine A2a receptor.
9 January 2025 | By Eurofins DiscoverX
Gain valuable insights into the latest advancements in obesity drug discovery and enhance your research capabilities.
Find out how Confo Therapeutics is overcoming challenges in GPCR drug development to create next-gen therapies for metabolic diseases.
Researchers at the University of Chicago have revealed the complete structure of adhesion GPCRs, uncovering new activation mechanisms that could lead to more targeted drug treatments.
A deep-learning model found metabolites and drugs that could be repurposed for non-addictive and non-opioid options to treat chronic pain.
20 June 2024 | By Eurofins DiscoverX
Join this webinar to discover how GPCR functional, cell-based assays determine off-target effects, reveal safety issues, and define drug mechanism of action to ultimately evaluate the therapeutic potential of candidate molecules.
Drug Target Review's Ria Kakkad spoke with Victoria Goldenshtein at PEGs Europe, about her lab’s novel in vitro library display platform for directed protein evolution called GRIP display – gluing RNA to its proteins.
Japanese researchers now reveal a new way of activating GPCR by triggering shape changes in the intracellular region of the receptor. This new process can help researchers design drugs with fewer or no side effects.
30 January 2023 | By Thermo Fisher Scientific
Watch this webinar to learn how an integrated structural biology workflow can be used to get crucial structural insights on key protein targets that are of therapeutic interest.
US researchers have found that G protein-coupled receptors function in a way not previously known, which suggests untapped potential.
In this exclusive Q&A, Drug Target Review’s Ria Kakkad spoke with Dr Jonathan Javitch, Professor at Columbia University’s Vagelos College of Physicians and Surgeons, about the cutting-edge imaging method single-molecule fluorescence resonance energy transfer (smFRET), used to investigate G protein-coupled receptors (GPCRs).
Dr Erik Vernet, Director of Antibody Technology at Novo Nordisk, discusses antibody discovery and development workflows, including the role of informatics processes, in this Q&A.
The new high-throughput screening method identified nine lead molecules for rhodopsin dimerisation that may lead to next-generation medicines.
A new computer-aided tool maps allosteric sites in G protein-coupled receptors to search for allosteric drugs to treat a range of diseases.
